Skip to main content
Premium Trial:

Request an Annual Quote

Acea, Vivo Biosciences Partner to Develop Assays for Roche's xCelligence System

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Acea Biosciences and Vivo Biosciences today announced a collaboration to further develop label-free and real-time cell-based assays for Roche's xCelligence System.

Terms of the deal were not disclosed.

The xCelligence system was co-developed by Acea and Roche and marketed by Roche Applied Science. New assays will incorporate Vivo Biosciences' HuBiogel platform, a human-derived, natural, biomatrix system. The platform, Roche said in a statement, facilitates the growth, proliferation, and differentiation of primary cells, cancer cells, and stem cells in a 3D format and physiologically relevant environment that resembles the in vivo environment.

The xCelligence system is comprised of RTCA Instruments with specially fabricated microplates that contain microelectrodes "for real-time, dynamic monitoring of cell behavior under label-free conditions," Roche added.

In a statement, James P. O'Connell, CEO of San Diego-based Acea Biosciences, said that the new HuBiogel assays "will increase the application field for the xCelligence System in low- and high-throughput formats."

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.